Browse

Welcome to another edition of Endpoints Weekly, and happy August! The summer is speeding right along, and we’ve got the latest from biopharma’s earnings-palooza this week. Let’s dive into the news.…

Novo Nordisk announced that its experimental cardiovascular drug ziltivekimab did not meet the primary endpoint in a Phase 3 study. The trial was designed to see if the drug could lower the inciden…